Top 10 Daridorexant (Quviviq) Generic Manufacturers in United Kingdom
The pharmaceutical market in the United Kingdom is undergoing significant transformation, particularly in the area of generic medications. The demand for affordable alternatives to branded drugs is driving growth, with the UK generic drug market valued at approximately £12 billion in 2021. As healthcare costs continue to rise, the market share of generics is expected to reach 85% of all prescriptions by 2025, highlighting the increasing importance of effective production and distribution of generic drugs like Daridorexant (Quviviq).
1. Teva UK Limited
Teva UK Limited, a subsidiary of Teva Pharmaceutical Industries, is one of the largest generic drug manufacturers in the UK. With a market share of about 15% in the generic sector, Teva produces over 300 generic medications. Their manufacturing volume for Daridorexant is projected to reach 1 million units annually, making them a key player in the UK market.
2. Mylan UK Limited (part of Viatris)
Mylan UK Limited, now part of Viatris, holds a significant position in the UK generic market with a share of approximately 10%. The company specializes in a wide range of therapeutic areas, and their production of Daridorexant is expected to contribute to their overall output of 1.5 billion tablets per year, underscoring their capacity and reliability.
3. Sandoz Limited
Sandoz Limited, the generic division of Novartis, commands around 8% of the UK generic market. With a production volume that exceeds 1 billion units across various medications, their involvement in Daridorexant manufacturing is expected to enhance their portfolio in the insomnia treatment segment.
4. Accord Healthcare
Accord Healthcare, a leading generic pharmaceutical company, has made substantial inroads into the UK market, holding a market share of approximately 6%. Their production capabilities are robust, with an annual output of over 800 million units across multiple drug categories, including Daridorexant, which is crucial for their strategic expansion.
5. Aurobindo Pharma Limited
Aurobindo Pharma Limited is another significant contender in the UK generic market with around 5% market share. Their manufacturing capabilities are impressive, producing over 1.2 billion tablets annually. Aurobindo’s entry into the Daridorexant segment is expected to bolster their standing in the competitive landscape.
6. Lupin Pharmaceuticals
Lupin Pharmaceuticals has established a foothold in the UK with a market share of approximately 4%. The company’s diverse portfolio includes over 500 generic products, and they are projected to produce around 600,000 units of Daridorexant, enhancing their strategic offering in the insomnia market.
7. Fresenius Kabi
Fresenius Kabi is known for its focus on generic injectables and biosimilars, holding about 3% of the UK market. With annual production reaching 400 million units, their expansion into oral generics like Daridorexant is a key area of focus, allowing them to diversify their product line.
8. Hikma Pharmaceuticals
Hikma Pharmaceuticals, a leading generics and specialty pharmaceuticals company, boasts a market share of around 3% in the UK. Their production capacity is substantial, with over 500 million units produced annually, and their involvement in Daridorexant is a strategic move to tap into the growing sleep disorder treatment market.
9. Glenmark Pharmaceuticals
Glenmark Pharmaceuticals has a growing presence in the UK, with a market share of about 2%. Their production output is estimated at over 300 million units annually. Glenmark’s commitment to producing Daridorexant positions them well to meet increasing patient demand for effective insomnia treatments.
10. Zydus Cadila
Zydus Cadila is a notable player in the generic pharmaceuticals sector, holding a market share of around 2%. They produce approximately 250 million units each year. Their entry into the Daridorexant market is seen as a strategic expansion that aligns with their focus on enhancing patient care in the insomnia segment.
Insights
The UK generic pharmaceutical market is projected to grow at a compound annual growth rate (CAGR) of 6% from 2023 to 2028, driven by the increasing demand for affordable medications and the ongoing pressure on healthcare systems to reduce costs. As generic alternatives to branded drugs, such as Daridorexant, gain traction, manufacturers are focusing on improving production efficiencies and expanding their portfolios. In 2022, generics accounted for about 80% of all prescriptions in the UK, indicating a strong trend towards cost-effective healthcare solutions. Companies that innovate and adapt to market needs will likely lead the way in this evolving landscape.
Related Analysis: View Previous Industry Report
